Amol Akhade: Top Sessions to Watch at ESMO GI 2025 – Clinical Innovation Meets Pragmatism
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, posted on LinkedIn:
“Top Sessions to Watch at ESMO GI 2025 – Clinical Innovation Meets Pragmatism.
The stage is set for a practice-shaping GI oncology congress in Barcelona.
Here’s a curated list of unmissable sessions blending late-breaking science, controversies, and cutting-edge innovation:
1. Late Breaking Abstracts – Clinical Gamechangers
Proffered Paper Session 1 | July 3, 14:00–15:30
- MATTERHORN (LBA4): Durvalumab + FLOT in resectable G/GEJ now reports EFS and PROs – adding patient-reported data to its clinical impact.
- PANOVA-3 (LBA3): Tumor Treating Fields in LAPC – updated QoL and pain outcomes support its role as a novel non-invasive adjunct.
- TALENTACE (LBA2): Phase 3 data on Atezo/Bev + TACE in HCC – may shift the standard for IO-loco regional therapy.
2. Controversy and Debate Sessions – Redefining Practice Norms
- Molecular Testing for All Pancreatic Cancer Patients – Should we test every patient? Golan vs O’Reilly go head-to-head.
- Organ Preservation in MSI Colon Cancer – Chalabi (Pro) vs Fernandez (Con). A pivotal debate on surgery-free approaches.
3. Special Symposiums – The Future is Now
- New Immunotherapy Concepts in GI: CAR-Ts, engineered TCRs, BiTEs, TRiTEs, RNA vaccines – in one powerhouse session.
- AI and Innovation in GI Oncology: From AI pathology to radioligands and proton therapy – real-world translational potential.
4. Educational Sessions – Building Evidence, Not Just Hope
- Pancreatic Cancer: From surgical boundaries to oligometastatic management and evolving metastatic strategies.
Localised Colon Cancer: The role of ctDNA, Immunoscore, and molecular profiling in neoadjuvant decision-making. - Biliary Tract Cancers: From surgery to targeted combinations – evidence backing evolving standards of care.
Why this matters:
GI cancers are complex and heterogenous. ESMO GI 2025 showcases how multi-modality, molecular-driven, and patient-centered strategies are taking center stage.”
More posts featuring Amol Akhade.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023